Medtronic announced that it will invest approximately $700 million in a strategic partnership with Hong Kong-based Cornerstone Robotics to obtain the rights to distribute its Sentire robotic surgical system in China, Singapore, and Europe. Medtronic will offer the system alongside its Hugo robot, expanding its soft-tissue surgery portfolio outside the United States.
Cornerstone developed the Sentire system in-house, and in May 2026 the robot received the European CE mark for use in general surgery and gynecological, thoracic, and urological procedures. The system also received the necessary approvals in China and Singapore, the markets covered by the announced distribution rights, as well as in several European markets.
What will the partnership change in practice?
Medtronic said that distributing Sentire in parallel with Hugo will give hospitals and surgeons broader options based on the clinical setting, procedure type, and economic model. Thus, the deal is not limited to injecting capital into Cornerstone; it also adds to Medtronic a robotic system ready for distribution in markets where it has obtained regulatory approvals.
Geoff Martha, Medtronic's chief executive officer, described the move as part of the company's global strategy and multiple investments in soft-tissue surgery. During the company's earnings call, he also rejected the notion that the investment reflects weak confidence in Hugo, saying the opposite was true and emphasizing the company's enthusiasm for the system's progress.
The competitive context
The partnership comes less than a year after Hugo received clearance from the U.S. Food and Drug Administration for use in urological procedures. This made Hugo the first soft-tissue robotic surgery system from a major medical device company to compete with Intuitive's da Vinci system in the U.S. market, according to the source material.
Johnson & Johnson's Ottava robotic surgical system also received authorization from the Food and Drug Administration in July 2026. In parallel, Medtronic submitted 510(k) applications to expand Hugo's use to general surgery and gynecology, and recently received clearance for an application that uses artificial intelligence to support decision-making during robot-assisted procedures.
Why does this news matter?
Medtronic is betting on a market in which the global penetration rate of robotic surgery remains in the single digits, while the rate in emerging markets is approximately 1%, according to Martha's comments to investors. The company says that Hugo is available in 35 countries and that the growth in procedures performed with it exceeds twice the growth rate of the robotic surgery market, with total procedures expected to exceed 50,000 by the end of its fiscal year and 250 units installed.
These figures and projections are attributed to Medtronic and do not by themselves establish the size of its future market share. The Sentire distribution rights have also been announced for specific markets outside the United States, and the material does not provide details on the cash value of the investment in exchange for the distribution rights, the timeline for beginning distribution, or the terms of the commercial partnership. Therefore, the practical impact will depend on the two systems' ability to address different clinical and economic needs, as well as on subsequent regulatory and commercial expansion.